GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (ASX:ZLD) » Definitions » EBITDA Margin %

Zelira Therapeutics (ASX:ZLD) EBITDA Margin % : -61,518.18% (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Zelira Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zelira Therapeutics's EBITDA for the six months ended in Dec. 2023 was A$-33.84 Mil. Zelira Therapeutics's Revenue for the six months ended in Dec. 2023 was A$0.06 Mil. Therefore, Zelira Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was -61,518.18%.


Zelira Therapeutics EBITDA Margin % Historical Data

The historical data trend for Zelira Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelira Therapeutics EBITDA Margin % Chart

Zelira Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -1,854.97 -763.85 -1,876.08

Zelira Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -722.94 -800.49 -4,361.04 -1,021.88 -61,518.18

Competitive Comparison of Zelira Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Zelira Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zelira Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's EBITDA Margin % falls into.



Zelira Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Zelira Therapeutics's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-5.647/0.301
=-1,876.08 %

Zelira Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-33.835/0.055
=-61,518.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zelira Therapeutics  (ASX:ZLD) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Zelira Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Zelira Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zelira Therapeutics (ASX:ZLD) Business Description

Traded in Other Exchanges
Address
101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

Zelira Therapeutics (ASX:ZLD) Headlines

No Headlines